We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

11 hedge funds and large institutions have $937K invested in Atossa Therapeutics in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

211% more capital invested

Capital invested by funds: $301K → $937K (+$636K)

83% more funds holding

Funds holding: 6 → 11 (+5)

Holders
11
Holders Change
+5
Holders Change %
+83.33%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$740K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$94.7K
3
Northern Trust
Northern Trust
Illinois
+$41.4K
4
Millennium Management
Millennium Management
New York
+$29.6K
5
Morgan Stanley
Morgan Stanley
New York
+$23.7K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$23.7K
2
TRCT
Tower Research Capital (TRC)
New York
-$12K
3
U
UBS
Switzerland
-$1K

ATOS Hedge Fund Activity: Q1 2014 in Review

11 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2014, worth a combined $937K — up 211% from $301K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ATOS positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $740K. The largest seller was Virtu KCG Holdings, cutting an estimated $23.7K.

  • 11 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2014, up from 6 in Q4 2013.
  • Funds reported $937K of Atossa Therapeutics stock for Q1 2014, up 211% quarter-over-quarter.
  • 6 funds opened new Atossa Therapeutics positions in Q1 2014 and 1 closed out, a net change of +5 holders.
  • The largest Atossa Therapeutics buyer in Q1 2014 was Vanguard Group, an estimated $740K added.
  • The largest Atossa Therapeutics seller in Q1 2014 was Virtu KCG Holdings, an estimated $23.7K sold.

Based on aggregated 13F filings for Q1 2014.